{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:11:02Z","timestamp":1789665062601,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"DOI":"10.1186\/s12896-026-01170-w","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:13:58Z","timestamp":1779534838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Jianhua","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"2","key":"1170_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.humpath.2009.07.002","volume":"41","author":"KB Hodges","year":"2010","unstructured":"Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol. 2010;41(2):155\u201362. https:\/\/doi.org\/10.1016\/j.humpath.2009.07.002.","journal-title":"Hum Pathol"},{"issue":"3","key":"1170_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.hoc.2021.02.002","volume":"35","author":"J Ma","year":"2021","unstructured":"Ma J, Black PC. Current perioperative therapy for muscle invasive bladder cancer. Hematol\/Oncol Clinics N Am. 2021;35(3):495\u2013511. https:\/\/doi.org\/10.1016\/j.hoc.2021.02.002.","journal-title":"Hematol\/Oncol Clinics N Am"},{"issue":"2","key":"1170_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41571-025-01095-x","volume":"23","author":"S Coca Membribes","year":"2026","unstructured":"Coca Membribes S, Szabados B, Powles T. Towards biomarker-driven therapies for urothelial carcinoma. Nat Rev Clin Oncol. 2026;23(2):92\u2013106. https:\/\/doi.org\/10.1038\/s41571-025-01095-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"1170_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2308849.","journal-title":"N Engl J Med"},{"issue":"12","key":"1170_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"key":"1170_CR6","doi-asserted-by":"publisher","unstructured":"Liu Y, Han X, Li L, Zhang Y, Huang X, Li G, et al. Role of nectin\u20114 protein in cancer (review). Int J Oncol. 2021;59(5). https:\/\/doi.org\/10.3892\/ijo.2021.5273.","DOI":"10.3892\/ijo.2021.5273"},{"issue":"8","key":"1170_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, et al. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphology. 2021;29(8):619\u201325. https:\/\/doi.org\/10.1097\/PAI.0000000000000938.","journal-title":"Appl Immunohistochem Mol Morphology"},{"key":"1170_CR8","doi-asserted-by":"publisher","first-page":"1678907","DOI":"10.3389\/fimmu.2025.1678907","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lu K, Xu Y, Xu S, Chu H, Fang X. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies. Front Immunol. 2025;16:1678907. https:\/\/doi.org\/10.3389\/fimmu.2025.1678907.","journal-title":"Front Immunol"},{"issue":"1","key":"1170_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 2013;82(1):775\u201397. https:\/\/doi.org\/10.1146\/annurev-biochem-063011-092449.","journal-title":"Annu. Rev. Biochem"},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","volume":"317","author":"P Debie","year":"2020","unstructured":"Debie P, Lafont C, Defrise M, Hansen I, van Willigen DM, van Leeuwen FWB, et al. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. J Control Release. 2020;317:34\u201342. https:\/\/doi.org\/10.1016\/j.jconrel.2019.11.014.","journal-title":"J Control Release"},{"key":"1170_CR11","doi-asserted-by":"publisher","first-page":"1334829","DOI":"10.3389\/fimmu.2024.1334829","volume":"15","author":"H De Greve","year":"2024","unstructured":"De Greve H, Fioravanti A. Single domain antibodies from camelids in the treatment of microbial infections. Front Immunol. 2024;15:1334829. https:\/\/doi.org\/10.3389\/fimmu.2024.1334829.","journal-title":"Front Immunol"},{"key":"1170_CR12","doi-asserted-by":"publisher","unstructured":"Hannula L, Kuivanen S, Lasham J, Kant R, Kareinen L, Bogacheva M, et al. Nanobody engineering for sars-cov-2 neutralization and detection. Microbiol. Spectr. 2024;12(4):e0419922. https:\/\/doi.org\/10.1128\/spectrum.04199-22.","DOI":"10.1128\/spectrum.04199-22"},{"key":"1170_CR13","first-page":"12","volume":"1","author":"PO Po","year":"2023","unstructured":"Po PO, Tillib SV. Single-domain antibody for binding the conserved epitope in the sars-cov-2 spike protein receptor-binding domain. Bull Russ State Med Univ. 2023;1:12\u201320.","journal-title":"Bull Russ State Med Univ"},{"issue":"4","key":"1170_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Kn\u00f6bl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1806311.","journal-title":"N Engl J Med"},{"issue":"1","key":"1170_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, et al. Nanobody-based car-t cells for cancer immunotherapy. Biomark Res. 2022;10(1):24. https:\/\/doi.org\/10.1186\/s40364-022-00371-7.","journal-title":"Biomark Res"},{"issue":"8","key":"1170_CR16","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","volume":"30","author":"Y Wu","year":"2022","unstructured":"Wu Y, Li Q, Kong Y, Wang Z, Lei C, Li J, et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022;30(8):2785\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.013.","journal-title":"Mol Ther"},{"issue":"11","key":"1170_CR17","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.7150\/thno.57510","volume":"11","author":"KT Xenaki","year":"2021","unstructured":"Xenaki KT, Dorresteijn B, Muns JA, Adamzek K, Doulkeridou S, Houthoff H, et al. Homogeneous tumor targeting with a single dose of her2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics. 2021;11(11):5525\u201338. https:\/\/doi.org\/10.7150\/thno.57510.","journal-title":"Theranostics"},{"issue":"1","key":"1170_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-021-00666-5","volume":"6","author":"J Fan","year":"2021","unstructured":"Fan J, Zhuang X, Yang X, Xu Y, Zhou Z, Pan L, et al. A multivalent biparatopic egfr-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Sig Transduct Target Ther. 2021;6(1):320. https:\/\/doi.org\/10.1038\/s41392-021-00666-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"12","key":"1170_CR19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","volume":"21","author":"M Rigby","year":"2022","unstructured":"Rigby M, Bennett G, Chen L, Mudd GE, Harrison H, Beswick PJ, et al. Bt8009; a nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors. Mol Cancer Ther. 2022;21(12):1747\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0875.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1170_CR20","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.3390\/molecules28093708","volume":"28","author":"MA Contreras","year":"2023","unstructured":"Contreras MA, Serrano-Rivero Y, Gonz\u00e1lez-Pose A, Salazar-Uribe J, Rubio-Carrasquilla M, Soares-Alves M, et al. Design and construction of a synthetic nanobody library: testing its potential with a single selection round strategy. Molecules. 2023;28(9):3708. https:\/\/doi.org\/10.3390\/molecules28093708.","journal-title":"Molecules"},{"issue":"3","key":"1170_CR21","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/ijms23031482","volume":"23","author":"B Liu","year":"2022","unstructured":"Liu B, Yang D. Easily established and multifunctional synthetic nanobody libraries as research tools. IJMS. 2022;23(3):1482. https:\/\/doi.org\/10.3390\/ijms23031482.","journal-title":"IJMS"},{"issue":"3","key":"1170_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","volume":"25","author":"C McMahon","year":"2018","unstructured":"McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol. 2018;25(3):289\u201396. https:\/\/doi.org\/10.1038\/s41594-018-0028-6.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"1170_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41598-018-37212-3","volume":"9","author":"T Ucha\u0144ski","year":"2019","unstructured":"Ucha\u0144ski T, Z\u00f6gg T, Yin J, Yuan D, Wohlk\u00f6nig A, Fischer B, et al. An improved yeast surface display platform for the screening of nanobody immune libraries. Sci Rep. 2019;9(1):382. https:\/\/doi.org\/10.1038\/s41598-018-37212-3.","journal-title":"Sci Rep"},{"issue":"1","key":"1170_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal R, Valderrama BP, Bellmunt J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol. 2024;21(1):8\u201327. https:\/\/doi.org\/10.1038\/s41571-023-00826-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1170_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.6004\/jnccn.2020.7539","volume":"18","author":"P Ghatalia","year":"2020","unstructured":"Ghatalia P, Plimack ER. Integration of immunotherapy into the treatment of advanced urothelial carcinoma. J Educ Chang Natl Compr Cancer Network. 2020;18(3):355\u201361. https:\/\/doi.org\/10.6004\/jnccn.2020.7539.","journal-title":"J Educ Chang Natl Compr Cancer Network"},{"issue":"3","key":"1170_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/CCO.0000000000000942","volume":"35","author":"WS Tan","year":"2023","unstructured":"Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao JJ. Evolving systemic management of urothelial cancers. Curr Opin Oncol. 2023;35(3):186\u201399. https:\/\/doi.org\/10.1097\/CCO.0000000000000942.","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"1170_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1817323.","journal-title":"N Engl J Med"},{"issue":"1","key":"1170_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MOU.0000000000001354","volume":"36","author":"N Roessler","year":"2026","unstructured":"Roessler N, Miszczyk M, Berger W, Englinger B, Eckstein M, Shariat SF. Nectin-4 in bladder cancer: biology and predictive biomarker potential. Curr Opin Urol. 2026;36(1):119\u201322. https:\/\/doi.org\/10.1097\/MOU.0000000000001354.","journal-title":"Curr Opin Urol"},{"issue":"6","key":"1170_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.semnuclmed.2025.09.003","volume":"55","author":"J Kabunda","year":"2025","unstructured":"Kabunda J, Ndlovu H, Singh K, Sibiya S, Mdanda S, Ramonaheng K, et al. Nectin-4, bladder cancer, and nuclear medicine: a theranostic frontier. Semin Nucl Med. 2025;55(6):912\u201327. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.09.003.","journal-title":"Semin Nucl Med"},{"key":"1170_CR30","doi-asserted-by":"publisher","unstructured":"Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, et al. Nectin4 is a novel tigit ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020;8(1):e000266. https:\/\/doi.org\/10.1136\/jitc-2019-000266.","DOI":"10.1136\/jitc-2019-000266"},{"key":"1170_CR31","doi-asserted-by":"publisher","unstructured":"Kobayashi G, Sekino Y, Hayashi T, Nakahara H, Yukihiro K, Kobatake K, et al. Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance. Virchows Arch. 2025. https:\/\/doi.org\/10.1007\/s00428-025-04164-9.","DOI":"10.1007\/s00428-025-04164-9"},{"issue":"29","key":"1170_CR32","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. JCO. 2019;37(29):2592\u2013600. https:\/\/doi.org\/10.1200\/JCO.19.01140.","journal-title":"JCO"},{"issue":"8","key":"1170_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","volume":"22","author":"W Zhou","year":"2023","unstructured":"Zhou W, Fang P, Yu D, Ren H, You M, Yin L, et al. Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E\u2013based antibody\u2013drug conjugate for treatment of Nectin-4\u2013expressing cancers. Mol Cancer Ther. 2023;22(8):913\u201325. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0743.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1170_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12951-024-02521-5","volume":"22","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhu M, Sun B, Chen Y, Huang Y, Gai J, et al. A humanized trivalent nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer. J Nanobiotechnol. 2024;22(1):256. https:\/\/doi.org\/10.1186\/s12951-024-02521-5.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"1170_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/24725552211000669","volume":"26","author":"F David","year":"2021","unstructured":"David F, Davis AM, Gossing M, Hayes MA, Romero E, Scott LH, et al. A perspective on synthetic biology in drug discovery and development\u2014current impact and future opportunities. SLAS Discov. 2021;26(5):581\u2013603. https:\/\/doi.org\/10.1177\/24725552211000669.","journal-title":"SLAS Discov"},{"issue":"17","key":"1170_CR36","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.3390\/ijms20174187","volume":"20","author":"X Cheng","year":"2019","unstructured":"Cheng X, Wang J, Kang G, Hu M, Yuan B, Zhang Y, et al. Homology modeling-based in silico affinity maturation improves the affinity of a nanobody. IJMS. 2019;20(17):4187. https:\/\/doi.org\/10.3390\/ijms20174187.","journal-title":"IJMS"},{"key":"1170_CR37","doi-asserted-by":"publisher","first-page":"1292839","DOI":"10.3389\/fimmu.2023.1292839","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Luan L, Liu X, Jiang D, Deng J, Xu J, et al. A novel nanobody-based her2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Front Immunol. 2023;14:1292839. https:\/\/doi.org\/10.3389\/fimmu.2023.1292839.","journal-title":"Front Immunol"},{"issue":"9","key":"1170_CR38","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.chembiol.2021.05.019","volume":"28","author":"JM Zupancic","year":"2021","unstructured":"Zupancic JM, Desai AA, Schardt JS, Pornnoppadol G, Makowski EK, Smith MD, et al. Directed evolution of potent neutralizing nanobodies against sars-cov-2 using cdr-swapping mutagenesis. Cell Chem Biol. 2021;28(9):1379\u201388.e7. https:\/\/doi.org\/10.1016\/j.chembiol.2021.05.019.","journal-title":"Cell Chem Biol"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-026-01170-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-026-01170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-026-01170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:51:44Z","timestamp":1789663904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12896-026-01170-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1186\/s12896-026-01170-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9113715\/v1","asserted-by":"object"}]},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study did not involve direct recruitment of human participants, collection of human tissue, or access to identifiable personal data by the authors. All data analyzed in this study were obtained from publicly available, de-identified databases, including TCGA, GEO, and the Human Protein Atlas; therefore, ethics committee\/institutional review board approval and informed consent were not required.Because this study was based exclusively on publicly available, de-identified data and did not involve direct human participation or collection of human specimens, the Declaration of Helsinki was not applicable to this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"114"}}